BioCentury
ARTICLE | Finance

Regulatory Milestones

Highlights of weekly biotech stock moves

May 3, 2010 7:00 AM UTC

Avanir Pharmaceuticals Inc. (NASDAQ:AVNR) gained $0.12 to $3.22 last week after the company submitted a complete response to a 2006 FDA approvable letter for Zenvia dextromethorphan/quinidine to treat pseudobulbar affect (PBA).

Pharmaxis Ltd. (ASX:PXS) lost A$0.10 to A$3.07 last week after FDA accepted for review an NDA resubmission for Aridol mannitol powder inhalation test to assess bronchial hyperresponsiveness to aid in the diagnosis of asthma...